Article · 6 Jan 2026
Conference abstractPublished 24 Sep 2018
Improved criteria for clinical, laboratory, molecular and pathologic (2018 clmp) diagnosis and staging of Prefibrotic JAK2, CALR And MPL mutated Myeloproliferative Neoplasms
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The broad spectrum of JAK2 V617F mutated trilinear myeloproliferative neoplasms (MPN) includes essential thrombocythemia (ET), prodromal polycythemia vera (PV), erythrocythemic PV, classical PV, masked PV and PV complicated by splenomegaly and myelofibrosis (MF). ET heterozygous for the JAK2 V617F mutation is associated with low MPN disease burden and normal life expectancy. JAK2 V617F mutation load increases from less than 50% in prodromal and early stage PV to above 50% up to 100% in combined heterozygous/homozygous or homozygous JAK2 V617F mutated PV, advanced PV and progressive myelofibrosis (MF). Pretreatment bone marrow morphology and cellularity distinguish JAK2 V617F mutated trilinear MPN from calreticulin (CALR) and MPL mutated MPN. The morphology of clustered large pleomorphic megakaryocytes with hyperlobulated nuclei is similar in JAK2 V617F ET and PV patients. CALR mutated thrombocythemia shows bone marrow characteristics of normocellular megakaryocytic (M) proliferation and subsequent dual megakaryocytic granulocytic (MG) myeloproliferation, first described in the 1990s as primary megakaryocytic granulocytic myeloproliferation (PMGM) without features of PV in blood and bone marrow. MPL515 mutated thrombocythemia is featured by the monolinear proliferation of large to giant megakaryocytes with hyperlobulated staghorn like nuclei. Natural history and life expectancy relate to the degree of splenomegaly, myelofibrosis, constitutional symptoms and increased allele burden in JAK2 V617F trilinear MPN and MPL515 thrombocythemia but CALR thrombocythemia runs a more favourable course during life-long follow-up. The acquisition of epigenetic mutations at increasing age predict unfavorable outcome in JAK2, CALR and MPL mutated MPN. Low dose aspirin in ET and phlebotomy on top of aspirin in PV is mandatory to prevent platelet-mediated microvascular circulation disturbances. Pegylated interferon is the first line myeloreductive treatment option in prodromal and early stage JAK2 V617F mutated PV and in CALR and MPL mutated thrombocythemia to postpone or obviate the targeted use of hydroxyurea and ruxolitinib as long as possible.
Subjects
Alternative & Palliative CareAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Alternative & Integrative Medicine.
Article · 29 Nov 2025
Ayurveda: Holistic Metabolic Syndrome Management
Article · 29 Nov 2025
Integrative Chronic Pain Management: A Holistic Approach
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAlternative & Integrative Medicine
- SubjectAlternative & Palliative Care
- BylineArticles whose byline prints “Jan Jacques Michiels”
- BylineArticles whose byline prints “Yonggoo Kim”
- BylineArticles whose byline prints “Myungshin Kim”
- BylineArticles whose byline prints “Vasily Shuveav”
- BylineArticles whose byline prints “Francisca Valster”
- BylineArticles whose byline prints “Vincent Potters”
- BylineArticles whose byline prints “Zwi Berneman”
- BylineArticles whose byline prints “Alain Gadisseur”
